Literature DB >> 21090969

Molecular genetics of colorectal cancer.

Eric R Fearon1.   

Abstract

Over the past three decades, molecular genetic studies have revealed some critical mutations underlying the pathogenesis of the sporadic and inherited forms of colorectal cancer (CRC). A relatively limited number of oncogenes and tumor-suppressor genes-most prominently the APC, KRAS, and p53 genes-are mutated in a sizeable fraction of CRCs, and a larger collection of genes that are mutated in subsets of CRC have begun to be defined. Together with DNA-methylation and chromatin-structure changes, the mutations act to dysregulate conserved signaling networks that exert context-dependent effects on critical cell phenotypes, including the regulation of cellular metabolism, proliferation, differentiation, and survival. Much work remains to be done to fully understand the nature and significance of the individual and collective genetic and epigenetic defects in CRC. Some key concepts for the field have emerged, two of which are emphasized in this review. Specifically, the gene defects in CRC often target proteins and pathways that exert pleiotropic effects on the cancer cell phenotype, and particular genetic and epigenetic alterations are linked to biologically and clinically distinct subsets of CRC.

Entities:  

Mesh:

Year:  2011        PMID: 21090969     DOI: 10.1146/annurev-pathol-011110-130235

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  696 in total

1.  Missense mutations in MLH1, MSH2, KRAS, and APC genes in colorectal cancer patients in Malaysia.

Authors:  Nor Azian Abdul Murad; Zulhabri Othman; Melati Khalid; Zuraini Abdul Razak; Rosniza Hussain; Sukumar Nadesan; Ismail Sagap; Isa Mohamed Rose; Wan Zurinah Wan Ngah; Rahman Jamal
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.

Authors:  Sara A Sajanti; Juha P Väyrynen; Päivi Sirniö; Kai Klintrup; Jyrki Mäkelä; Anne Tuomisto; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-11-14       Impact factor: 4.064

3.  Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Authors:  Hongliang Liu; Wei Liu; Bin Zhu; Qiang Xu; Xiaowei Ni; Ji Yu
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

Review 4.  High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer.

Authors:  Agnieszka B Bialkowska; Vincent W Yang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

5.  Micromanaging the classification of colon cancer: the role of the microRNAome.

Authors:  Eduardo Vilar; Josep Tabernero; Stephen B Gruber
Journal:  Clin Cancer Res       Date:  2011-10-21       Impact factor: 12.531

6.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

Review 7.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

8.  From the Cover: PhIP/DSS-Induced Colon Carcinogenesis in CYP1A-Humanized Mice and the Possible Role of Lgr5+ Stem Cells.

Authors:  Jayson X Chen; Hong Wang; Anna Liu; Lanjing Zhang; Kenneth Reuhl; Chung S Yang
Journal:  Toxicol Sci       Date:  2016-09-23       Impact factor: 4.849

Review 9.  Update on Sporadic Colorectal Cancer Genetics.

Authors:  Karin M Hardiman
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

Review 10.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.